drugset / Trial / NCT01332799

Xanthine Oxidase Inhibition in Renal Transplant Recipients

NCT01332799

Phase 4 Terminated 20 enrolled University of Iowa
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.

Timeline

Start
2011-02
Primary completion
2018-08-10
Completion
2018-08-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule Oral